ACT vs JPM

ACT's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential operational inefficiencies despite strong profitability. The absence of an Altman Z-Score raises concern about default risk, especially given the sector's average debt levels. While the company trades below its Graham Number ($61.88) and intrinsic value ($133.34), its current price of $40.49 reflects a significant discount, likely due to low growth and weak financial stability signals. Insider selling activity over the past six months adds bearish sentiment, and analyst consensus remains at 'hold' with limited upside. The stock's strong historical earnings surprises and high margins are offset by stagnant revenue growth and elevated peer P/E multiples.

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.